PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program

PDS Biotechnology Corporation (NASDAQ: PDSB ) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer. PDS0301 Metastatic Colorectal Cancer Focus PDS Biotechnology is prioritizing its PDS0301 program, which targets metastatic colorectal cancer, as part of a strategic refocus. This decision reflects the company's commitment to advancing its immunotherapy pipeline, which leverages its proprietary Versamune platform technology. The company on Tuesday said, "We concluded that our resources should be redirected toward PDS0301, where we believe the combination of encouraging clinical data, development opportunity and capital requirements provide a potentially more attractive path to long-term shareholder value." Read Also: Natera Secures Landmark Japan Nod For Signatera In Colorectal Ca...